NEW YORK (GenomeWeb) – Qiagen said this week that it will be begin offering a quality control set and verification data with its GeneReader NGS System. The company will integrate Horizon Discovery Group's industry-standard reference control data set into the GeneReader NGS workflow. Further, Qiagen said its GeneRead QIAact Actionable Insights Tumor Panel has demonstrated accuracy, consistency, and reliability in testing compared with Horizon's control data.